



Pioneers bringing pharmaceutical industry expertise to the world of medicinal cannabis

DR. Miri Halperin Wernli, CEO
MR. David Russell, COO

Disclaimer

This presentation has been prepared by Creso Pharma Limited (Company or Creso). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso. This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and any

such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.

A Nascent Industry in Need of Expertise

- The medicinal cannabis industry is in its infancy and dominated by small players with minimal understanding of what is required to comply with emerging regulations
- This has led to questionable quality due to the lack of standardization in formulation and dosage of cannabis derived products
- There is a remarkable lack of trusted cannabis brands in the global marketplace
- Established pharmaceutical companies are generally reluctant to enter the market due to evolving regulations

**Creso brings
significant
pharmaceutical
industry expertise
and rigor to the
world of medicinal
cannabis**

Creso Pharma brings pharmaceutical expertise and methodological rigor to the world of medicinal cannabis and strives for the highest quality in its products.

MISSION

Creso Pharma is the leader in cannabidiol (CBD) innovation and develops cannabis and hemp-derived therapeutic grade nutraceuticals and medicinal cannabis products with wide patient reach for human and animal health.

CRESO PHARMA LTD

Geographically diversified and vertically Integrated Company

CANADA:

Medicinal cannabis now and future adult/recreation use July 1 2018

Opportunity: Cultivation, extraction, medicinal cannabis, cannaQIX[®], anibidiol[®], exports, R&D, innovative products

Creso Pharma is the only Australian cannabis company with direct exposure to the largest legal market in the world:
Canada

LATIN AMERICA:

SwissVit[™] distributor Sin Solution signed LOI. cannaQIX[®] and anibidiol[®] partner search underway

SWITZERLAND & EU:

Human and animal hemp-derived nutraceuticals cannaQIX[®] and anibidiol[®].

First launch country is Switzerland as a reference market.

Terpene products in development.

JAPAC:

SwissVit[™] & cannaQIX[®] with partner search underway in parallel with regulatory assessment by key market

AUSTRALIA:

Medicinal Cannabis market due to regulatory scheduling

Opportunity: cannaQIX[®] & anibidiol[®], cultivation and local product development with LeafCann partnership, R&D collaborations

Creso Pharma Ltd: ASX:CPH


IPO Oct 2016	\$m	5.0m (Oversubscribed)
Capital Raising Mar 2017	\$m	9.0m (Oversubscribed)
Market Cap @50 cents*	\$m	45.2m
Cash at Hand	\$m	8.0m
Enterprise value	\$m	~37.2m
Shares on Issue	no.	90.4m
Top 20 shareholders	%	51.1%
Escrowed Shares	No.	15.6m (29.9% of Shares On Issue)



Global development, registration and commercialization of pharmaceutical grade cannabis and hemp derived therapeutic products using innovative delivery technologies

1. GMP sourcing only
2. Standardised full-plant extraction
3. Owning unique delivery methods
4. Quality sales & distribution channels
5. Clinical Trials in human and animal health
6. IP development across the value chain

Corporate Structure



*In process of incorporation



Board of Directors



Dr. Miri Halperin Wernli
CEO & CO-FOUNDER

Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries.

She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US.



Boaz Wachtel
CHAIRMAN & CO-FOUNDER

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publicly traded medical cannabis company.

He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland



Adam Blumenthal
NON-EXECUTIVE DIRECTOR & CO-FOUNDER

Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies.

He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.



Dr. James Ellingford
Non-Executive Director

Dr. Ellingford's professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA.

He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.

Commercial and Market Access Advisors



David Russell
CHIEF
OPERATING
OFFICER

Mr. Russell has more than 25 years' experience within the pharmaceutical and biotech industry with a number of leading global companies including Roche, Actelion, Celgene and Novogen.

In particular, he has been responsible for building, leading and growing commercial teams and product launches in China, Australia and Asia in a number of therapeutic areas.



Jorge Wernli
INDUSTRY
ADVISOR

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups.

Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.



Dr. Gian Trepp
INDUSTRY
ADVISOR

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership.

He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.

Scientific Advisory Board



**Dr. Isaac
Kobrin**
INDUSTRY
ADVISOR

Dr. Isaac Kobrin is an internist with 15 years experience in the academic medicine both in Israel and the USA. He has over 22 years of experience in the Pharma Industry in Roche and Actelion.

He has been responsible for the worldwide development of key compounds and has held numerous leadership positions in medical organisations.



**Dr.
Stéphane
Redey**
INDUSTRY
ADVISOR

Dr. Stéphane Redey has over 18 years experience leading teams in the technical development of innovative drugs and strategic outsourcing. He has held senior positions with global responsibilities in pharmaceutical companies in both Switzerland and Australia.

He has led successful international collaborations with companies on four continents.



**Dr. Raquel
Peyraube**
INDUSTRY
ADVISOR

Dr. Raquel Peyraube is a specialist in the drug field with more than 28 years experience. Throughout her career she has been involved in training, prevention, treatment and harm reduction, developing innovative approaches emphasising ethical issues which has earned her international recognition.

Dr Peyraube is currently a consultant on drug policy reform in Latin America.



**Prof. Dr.
med Felix
Gutzwiller**
INDUSTRY
ADVISOR

Felix Gutzwiller holds the titles of MD of the University of Basel, an MPH of the Harvard School of Public Health, Dr. PH of the Johns Hopkins University School of Hygiene and Public Health.

He was a Professor at the University of Basel and a Professor of Social and Preventive Medicine at the University of Zürich (1988-2013), Emeritus since 2013.

Achievements since IPO



A stylized graphic of a plant with several overlapping, teardrop-shaped leaves. The leaves on the left are filled with a vibrant green color, while the leaves on the right are rendered as dark grey outlines. The entire graphic is centered vertically and horizontally on the page.

Mernova Medicinal Inc.

A Compelling Combination


A vertically integrated cannabis company offering a unique intellectual property portfolio, experience in cannabis and pharmaceutical grade products, with ample production capacity and access to the world's largest legal market:

- Fully funded acquisition with facility construction to be financed with cash on hand
- Extensive pharmaceutical industry expertise and methodological rigor
- Unlocking the full cannabis industry value chain including, R&D, GMP cultivation, extraction, and marketing
- Scale in production, marketing, sales and distribution
- Autonomous control of production and extraction chain
- Patented, proprietary buccal (THC and CBD) delivery technologies which enhance the bioavailability and absorption of cannabinoids
- Delivers on Creso's strategy of establishing a Canadian presence in the pursuit of opportunities in the medicinal and recreational cannabis space

Significant Value for Creso Shareholders

- CPH is trading at an attractive valuation relative to North American listed peers
- Entry into the Canadian market, with in country sales valued at between C\$8 - 9 billion by 2024
- Diversified and enhanced revenue profile
- Accelerates the ability to innovate and bring product to market, with access to five universities, research and development tax credits, and government funding programs for commercialisation
- Reduces risk of reliance on third parties and protects Creso's ability to innovate, build and protect a cannabis IP portfolio for future commercialisation
- Only medicinal cannabis company listed on the ASX with the capacity to commercially cultivate medicinal-grade cannabis in the Canadian federally regulated environment
- Clear path to regulation and legalisation: Legislation to open a recreational market was tabled by the Canadian government in 2017 and is expected to be implemented by the end of June 2018
- Opens a potential gateway to the United States market in the future
- Supportive government with low cost of electricity, pay roll rebates, and access to provincial funding programs


Canada: Demand Growing in The World's Largest Market*



*All figures in Canadian dollars. Health Canada, equity research, and Creso Pharma projections



Canada: Demand Growing in The World's Largest Market*



*All figures in Canadian dollars. Health Canada, equity research, and Creso Pharma projections



Canada: 1st G7 Country to Legalise Cannabis




*projections include recreational cannabis use.
**All figures in Canadian dollars. Deloitte Touche Tohmatsu Limited, Recreational Marijuana: Insights & Opportunities, 2016



Mernova: Production Facility

- Accelerates the ability to innovate and bring product to market: 20,000 sq. ft. facility is expected to produce 2,000,000 – 4,000,000g of cannabis annually
- Scalable up to 200,000 sq. ft. to grow with demand, as the recreational market comes into existence, making it a measured investment: 200,000 sq. ft. facility is expected to produce 20,000,000 – 40,000,000g of cannabis annually
- Will utilise the best growing practices to ensure the safest and highest quality product and consistent crop yields
- Upon completion of the GMP facility, Mernova Medicinal will access the market as a large-scale high-quality producer of medical cannabis
- Built and operated to GACP and GPP (GMP) standards to ensure that it can expand research and development capability for Creso Pharma
- Clear path to regulation and licensing: Mernova Medicinal applied for a cultivation licence in 2014 and is progressing through the final approval process, which will include regular inspection of its facilities to ensure safety, professionalism and compliance
- Intention to also build a state of the art GMP compliant CO₂ extraction facility to enable the company to sell high quality extracts into the Canadian market and for use in Creso's other product development

Mernova: Timelines and Milestones



Mernova: Management Team and Consultants



**Bill
Fleming**
CEO

Mr. Fleming has founded and served as CEO for a number of entrepreneurial companies and has served with senior executive teams dealing with equity and debt financings. He has developed corporate strategies for a wide range of companies, from family-owned businesses to multi-national companies.

He is the Executive Chairman of Mountain Lake Minerals. Previously he was the CFO and Director for NWest Energy Corporation.



**Charles
Williams**
QUALITY
ASSURANCE

Dr. Williams completed a Ph.D. in Organic Chemistry at McGill University in 1991. He spent four years as an Evaluation Officer in the Health Evaluation Division of the Pest Management Regulatory Agency (PMRA) of Health Canada.

He founded CRW Regulatory Services Inc. and has extensive experience and training in Good Laboratory Practice procedures and requirements, Good Manufacturing Practices and an understanding of the techniques related to the production of pure products.



**Georges
Routhier**
PIPEDREEMZ
CONSULTANT

Georges Routhier is qualified as a systems engineer and in GMP. He has worked as the Director of Operations and Master Grower at CCMed Inc. in Ottawa before moving to Delshen as Chief Development officer.

Since 2013 Georges has been CEO of Pipedreemz Inc. specialising in consulting to medicinal cannabis companies and ACMPR application. Georges experience in application process, SOP's and site planning, builds and security Pipedreemz has delivered support to 12 successful licence producers in Canada.


A stylized graphic of cannabis leaves is centered on the page. The leaves are arranged in a fan-like pattern, with some overlapping. The left side of the leaves is set against a solid green background, while the right side is set against a dark gray background. The leaves themselves are rendered in a light green color on the left and a light gray color on the right.

Why Cannabis?

Cannabis and Hemp Entourage Effect From Full Plant Extracts


Creso only uses **full plant extracts**.

Cannabinoids and other compounds have a greater effect when taken together than when separated into individual single compounds - potentially resulting in a **synergetic entourage effect**¹



Cannabidiol (CBD)

CBD is the second-most prominent compound found in the Cannabis Sativa plant, after THC and is non-psychoactive



A stylized graphic of a plant with several leaves. The left side of the image is a solid green background, and the right side is a dark gray background. The leaves are outlined in a lighter green on the left and a lighter gray on the right, creating a symmetrical effect across a vertical line.

Market Potential

Market Potential

Australia: No data exists for potential but estimates of AU\$150m for medicinal cannabis are reasonable

Global: Sales now exceeding \$4.5 billion


US: A 3 million-patient market opportunity (More than 700K patients have already been prescribed) and expanding

Canada: Estimated at \$144 million in 2014, rising to \$380 million by 2018, to \$1.3 billion by 2024. Currently 167,000 patients on product growing six fold in two years[#]


Switzerland: Medicinal cannabis market expanding and recent publication gives an indication of usage in 2013/14*

Europe: Vast unmet demand. Small quantities usually imported from Holland's only national medical-grade cannabis program supplier - Bedrocan. Value figures unavailable

ArcView & BDS Analytics



New Frontier Analytics



Growth in Human Health Markets



Nutraceuticals are a multi-billion dollar industry

- Total global nutraceuticals market reached **\$142.1 billion** in 2011
- Expected to reach **\$204.8 billion** by 2017
- The nutraceutical ingredient market is forecast to reach **\$33.6 billion** by 2018
- The overall US nutrition market was estimated at **\$137.4 billion** in 2012, with supplements accounting for **\$32.4 billion**



Multiple drivers for continued growth

- Rising health concerns, the growth of key demographics and growing consumer desire to lead a healthy life and avoid dependence on synthetic drugs are identified trends that show no sign of slowing down



Extremely lucrative for food and beverage companies

- Comparatively high margins
- Minimal regulatory requirements
- Germany, Switzerland, Netherlands, and Sweden have emerged as the key nutraceutical innovation hubs in Europe
- Australia has a quality reputation for vitamins and dietary supplements throughout Asia

Ability to Fulfil the Unmet Market Need

The market for nutraceutical cannabinoids is still untapped

1

Generally, no GMP-certified production to produce standardized high-grade plant extracts

2

Lack of efficacious delivery systems to ensure sufficiently high bioavailability and absorption

3

Lack of seasoned pharmaceutical executives to develop products and launch brands in this area

A stylized graphic of a plant with several overlapping, teardrop-shaped leaves. The leaves on the left are filled with a vibrant green color, while the leaves on the right are rendered as dark grey outlines. The background is split vertically: the left half is solid green, and the right half is a dark grey gradient.

The Creso Advantage

A large, stylized graphic of a leaf or plant structure, rendered in a light teal color, occupies the left side of the image. It features several pointed, overlapping shapes that resemble leaves or petals, extending from the left edge towards the center.

Human Health Nutraceuticals



- Hemp-based nutraceutical product
- Stimulates psychological performance to reduce stress, and enhance mental focus and overall health
- Proprietary delivery technologies enhancing bioavailability and absorption
- Fully Pharma-grade GMP development and production
- Reliable & safe, non-euphoric, non-addictive
- Strong scientific rationale to back the introduction in the area of anxiety and stress
- Product Launch Q2 2018 in Switzerland as a pharmaceutical grade OTC product
- CannaQIX® conforms to Swiss Food Laws and Regulations and is an approved product with a full market authorization in Switzerland
- Geographical expansion discussions with commercial partners ongoing to Europe, Middle East, Latin America, South Africa, and JAPAC



Creso Product Range - Life Cycle Management - Technology 1

Product	Stage	CBD Strength (mg)	Pack Size	Qix's (g)	Flavour	Delivery system
cannaQIX® 5	D	5	30 / 60	2g	caps/ginger	Gum arabic
cannaQIX® 10	RFL	10	30 / 60	2g	caps/ginger	Gum arabic
cannaQIX® 50	D	50	30	2g	lime	Gum arabic

RFL: Ready for launch
 D: in development



A large, stylized leaf graphic is positioned on the left side of the slide, spanning across the vertical color boundary. The leaf is composed of several overlapping, curved segments that form its veins and outline. The left portion of the leaf is light beige, while the right portion is dark grey, matching the background. The text is centered over the dark grey area.

Animal Health: Complementary Feed

Animal Health Nutraceutical Products

- Creso has a range of hemp-based complementary feed products for companion animals in proprietary delivery technologies
- Creso's hemp extract was registered on the European Feed Materials Registry earlier this year and Agroscope, the Swiss authority responsible for safe feed in Switzerland and trade from Switzerland, has issued Free Sales Certificates for anibidiol® for companion animals
- Creso Pharma has signed an exclusive commercialisation agreement with Virbac, a global pharmaceutical animal health company
- The Swiss launch of anibidiol® 1.25 and anibidiol® 2.5 is on schedule for Q4 2017
- The anibidiol® product range addresses the need for GMP non-pharmaceutical therapeutic approaches which are natural and well tolerated by the animals, for example avoiding GI and dependence side effects



Creso Brands: anibidiol[®] 1.25 and anibidiol[®] 2.5

- The products are aimed at companion animals and address stress and behavioural disorders, chronic pain (mainly arthritis), and age-related ailments in ageing animals
- They contain full-plant hemp extract in proprietary formulations promoting the well being of the animals by supporting the immune system and the natural response, as well as supporting the animal's behavioural balance
- Globally 33% of households have a dog¹
- 2.3m households have more than one pet in Australia
- One of the biggest challenges of pet ownership is maintaining pets health
- 41% of pet owners have considered or tried various alternative therapies:
 - Nutritional supplements (29%)
 - Herbal remedies (7%)
 - Homeopathy (4%)



A large, stylized graphic of a leaf or plant branch, split vertically. The left half is a solid teal color, and the right half is a dark grey color. The graphic is composed of several overlapping, semi-transparent shapes that create a sense of depth and movement.

SwissVit™ Nutraceuticals



Swiss
Made

SWISS BY NAME. SWISS BY NATURE.
Vitality Precisely

Premium Swiss Nutraceuticals in patented INNutri[®] delivery technology


- Soft Gum[™] technology for buccal delivery
- Precise dosing, immediate release and increased absorption into circulation
- Gelatin free
- Vegan & Vegetarian
- Non sticky – to teeth or each other
- Gluten & GMO-free
- Optionally halal or kosher
- Natural colours & flavours
- Enables processing/inclusion of heat-sensitive actives, which is technically not possible for gelatin products
- Mono or centre filled; filling represents 5 to 15%
- Much more convenient compared to tablets, effervescent products and capsules
- Ideal weight per Soft Gum[™] 3.5g, scope from 2.5 to 5g
- Meets the needs of consumers who need to be motivated and those who struggle with swallowing (elderly, children)



Break-through technology offering a unique opportunity to accelerate sales in a fast growing, multi-billion dollar marketplace

A wide variety of Premium Swiss Nutraceutical Options for Launch

- Multivitamins
- Bone & Joint
- Immunity
- Eye Health
- Cardiovascular Function
- Lactose Breaker
- Bone & Heart
- Health Boost
- Antioxidant
- Health Protection
- Blood Formation
- Anti-Aging
- Digestion Aid
- Sunactive Iron
- K2 & K3



A stylized graphic of a cannabis leaf is centered on the page. The leaf is composed of several overlapping, rounded shapes that form its lobes. The left side of the leaf is set against an orange background, while the right side is set against a dark grey background. The leaf itself is rendered in a light orange color on the left and a dark grey color on the right.

Medicinal Cannabis

Medicinal Cannabis: Australia

- Creso Pharma's Australian partner, Health House International, successfully imported the first medicinal cannabis products into Australia in May 2017 following changes to Government legislation
- Import was a range of three cannabis oils for human health from Canadian manufacturer CanniMed
- The oils can be used for a variety of conditions as approved by prescribing physicians under Australian Federal and State laws and regulations to meet immediate need for medicinal cannabis locally
- Products will now be distributed to authorised pharmacies by Health House



Medicinal Cannabis: Australia

- LOI Signed with Cannapharm AG, Switzerland to exclusively distribute the fully GMP Swiss medical cannabis products in selected territories
- THC/CBD:
 - 10:20 in the alcohol extraction
 - 10:25 in the hemp oil extraction
- Exclusive Territory: Australia, New Zealand, China, Brazil, Mexico, Chile, Colombia



In-Line Product Pipeline and Brands

Full Plant CBD-rich Nutraceuticals

Animal Hemp-based Complementary Feed

First Delivery System

- anibidiol® 1.25 Small Companion Animals
- anibidiol® 2.5 Small Companion Animals
- anibidiol® 40 Large Companion and Zoo Animals

Second Delivery System

- anibidiol® 100 Small Companion Animals
- anibidiol® 400 Large Companion and Zoo Animals

Human Health

- CannaQix® in 1st Proprietary delivery system
- CannaQix® in 2nd Proprietary delivery system
- CannaQix® Line extension in proprietary delivery systems


Anxiety/Stress

Bone

Medical Cannabis & SwissVit™

Human Health

- SwissVit™ Range of nutraceuticals in INNutriGEL SoftGum® technology
- Australia Medicinal Cannabis (CanniMed®)
- Australia Medicinal Cannabis (Cannapharm AG)
- Australia Medicinal Cannabis (LeafCann)



A stylized graphic of a plant with several overlapping, teardrop-shaped leaves. The leaves on the left are filled with a vibrant green color, while the leaves on the right are rendered as dark grey outlines. The entire graphic is centered vertically and horizontally on the page.

Business Development

Investigation Phase Business Development

SwissVit™ Soft Gums™ using propriety INNutriGEL® patents via distribution agreement in Latin America and under assessment are Australia, China and Asia-Pacific

Australian cultivation and product development via the partnership with LeafCann Australia

Clinical Trials under consideration by the Scientific Advisory Board in Anxiety, Stress, ageing and Dementia using Swiss GMP CBD/THC products

Terpene based products using formulations unique to Creso and linked to proprietary technologies with global exclusivity

Enter edibles market with proprietary hemp based products

Cosmetics projects "A" and "B" with propriety CBD rich full-plant extracts

Comprehensive Approach

1

GMP sourcing only: nutraceutical products from GMP-certified plants located in Europe, syndicated to our needs

2

Standardized extraction: GMP and/or ISO-compliant extraction processes, to supply products of excellent quality, purity, and safety

3

Owning and developing unique delivery methods: source and license innovative and proven delivery platforms including tablets and sub-linguals to increase absorption and bioavailability

4

Sales channels: Products will be sold online in territories with full registration files approved by the health authorities

5

Clinical trials: perform small-scale clinical trials to gain scientific data

6

IP: Secure IP across the value chain

Hemp based full-plant medical grade CBD-rich nutraceutical products which are efficacious, safe, standardised in composition and dose

Business Model



Near Term Revenues

Product Development and Launches are in process and on track

anibidiol[®] launch in Switzerland with Virbac (Q4 2017)

cannaQIX[®] launch in Switzerland (Q2 2018) and expansion to EU, Middle East, JAPAC

Medicinal Cannabis product growth in Australia with LeafCann

Canadian facility product comes Sept. 2018

SwissVit[™] availability through distribution agreements

A stylized graphic of a plant with several overlapping, teardrop-shaped leaves. The leaves on the left are filled with a vibrant green color, while the leaves on the right are rendered as dark grey outlines. The entire graphic is centered vertically and horizontally on the page.

Investment Summary

Investment Proposition



Fills void in current market with growing need for **trusted products** that meet the highest global pharmaceutical standards



Near-term revenues Animal product launch in Switzerland in Q4 2017 with further animal and first human product launches in Switzerland and selected EU countries in 2018



Growing market opportunity with a **number of products in pipeline** targeting human and animal nutraceutical markets



Exclusive licensing deals that gives Creso access to unique drug delivery IP and substantial distribution globally



Diversified revenue stream targeting human and animal health markets




Access to the **global market** that is only at the start of its growth through vertical integration



Company well placed to be the **“gold standard”** in cannabis and hemp derived therapeutics

Next 18 Months



Investment Summary



Rapidly Growing Markets

- Increasing scientific evidence on efficacy of cannabis-based treatments
- Existing markets are expanding and new markets opening
- More countries are liberalising medicinal cannabis

Increased Consumer Demand



Strongly Performing Sector

- Investor interest in sector is strong
- 50+ companies with business based largely on legal marijuana
- Industry in infancy with plenty of room to grow

Strong Sales Revenue



"Gold Standard"

- Creso brings pharmaceutical industry rigour and professionalism to medicinal cannabis market
- Company well placed to be the gold standard in cannabis and hemp derived therapeutics

Industry Leadership



Sound Business Model

- Near-term revenues
- Diversified revenue streams from human and animal health markets
- Canadian expansion with Mernova
- Best practice for CBD extraction and drug delivery
- Resources in place for global sales

Strong Company Returns



CRESO

PHARMA

Contact Information

Creso Pharma Limited

t: +61 8 6381 0054
e: info@cresopharma.com

Level 4
11 Ventnor Avenue
West Perth WA
Australia

Mirador Corporate

Company Secretary

t: +61 8 6381 0054

Level 4
11 Ventnor Avenue
West Perth WA
Australia

EverBlu Capital

Corporate Advisor

t: 02 8249 0000
e: info@everblucapital.com
w: www.everblucapital.com

Level 39
Aurora Place
88 Phillip Street
Sydney NSW
Australia